DANIEL CROWE: Open Payments
NPI 1720622038 · OWENSBORO, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$685 in 42 payments from 12 companies in 2025. Trend: 2023 $577 · 2024 $423 · 2025 $685
Food & beverage: $685
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $141 |
| Neurocrine BioSciences, Inc. | 5 | $100 |
| Janssen Pharmaceuticals, Inc | 5 | $99 |
| Axsome Therapeutics, Inc. | 4 | $79 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $65 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Lundbeck LLC | 2 | $33 |
| Biogen, Inc. | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
Products named: VRAYLAR, INGREZZA, SPRAVATO, Auvelity, CAPLYTA, REXULTI, ZURZUVAE, ABILIFY ASIMTUFII.
Industry payments across KY — which companies pay providers there.
